Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW -- Ignore unavailable to you. Want to Upgrade?

To: LORD ERNIE who wrote (748)	5/20/2000 4:27:00 AM
From: LORD ERNIE	Read Replies (1) \| Respond to of 857

Hemispherx Announces First Quarter Results PHILADELPHIA, May 15, 2000 /PRNewswire via COMTEX/ -- Hemispherx Biopharma, Inc. (Amex: HEB, HEBws) reported today a net loss (including non cash stock compensation expense) of $1,972,056 or $.07 per share for the three months ending March 31, 2000 versus a net loss of $2,900,053 or $.11 per share for the same period in 1999. The reduced net loss of $927,997 in the first quarter of 2000 versus the first quarter of 1999 consists of increased revenues, coupled with lower manufacturing costs and reduced General and Administrative expenses. Revenues from the Company's ME/CFS treatment programs in Europe and North America increased 59%, substantially higher than in any previous quarter. Manufacturing costs in the first quarter of 2000 decreased approximately $800,000 compared to the first quarter of 1999. In 1999, the Company invested heavily in the procurement of raw materials to be used in the manufacturing of the Company's Investigational Drug tradenamed "Ampligen." This build-up of raw materials was to support the Company's ongoing clinical programs. Clinical and R&D costs increased $551,779 in the first quarter of 2000. Clinical trial costs increased due to the accelerated enrollment of patients in the Company's ME/CFS clinical trial in the United States. The Company has been actively enrolling ME/CFS patients needed to complete the FDA authorized confirmatory pivotal tests. General and Administrative costs decreased by approximately $351,000 on a quarter to quarter basis. The Company took certain actions to reduce costs, including legal fees, consultant fees and public relations expense. Stock compensation expense was reduced by $222,000 from the first quarter of last year. Stock compensation expense reflects the fair value of the common stock including warrants granted to non-employees of the Company. The Company's overall cash position increased $3,579,718 in the period December 31, 1999 to March 31, 2000. Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. SOURCE Hemispherx Biopharma, Inc. CONTACT: William A. Carter, M.D., CEO & Chairman of Hemispherx Biopharma, Inc., 215-988-0080, or fax, 215-988-1739; or Mark Kollar of Broadgate Consultants, 212-232-2222, or fax, 212-232-3232; or Dianne Will, Investor Relations, 214-954-9300, or fax, 214-954-9333, both for Hemispherx /Web Site: hemispherx.com (HEB)